The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: what do we know and where are we going?

Publication date: Available online 10 November 2016
Source:Cancer Treatment Reviews
Author(s): Julian C. Hong, Joseph K. Salama
The spectrum hypothesis posits that there are distinct clinical states of metastatic progression. Early data suggest that aggressive treatment of more biologically indolent metastatic disease, characterized by metastases limited in number and destination organ, may offer an opportunity to alter the disease course, potentially allowing for longer survival, delay of systemic therapy, or even cure. The development of stereotactic body radiation therapy (SBRT) has opened new avenues for the treatment of oligometastatic disease. Early data support the use of SBRT for treating oligometastases in a number of organs, with promising rates of treated metastasis control and overall survival. Ongoing investigation is required to definitively establish benefit, determine the appropriate treatment regimen, refine patient selection, and incorporate SBRT with systemic therapies.



http://ift.tt/2fq8UDZ